Atara Biotherapeutics (ATRA) stock Forecast for 2022 – 2026
Last update: 05-20-2022, 12:38Sector: Healthcare
The share price of Atara Biotherapeutics, Inc. (ATRA) now
What analysts predict:: $27.57
52-week high/low: $20.04 / $4.84
50/200 Day Moving Average: $8.15 / $13.66
This figure corresponds to the average price over the previous 50/200 days. For Atara Biotherapeutics stocks, the 50-day moving average is the resistance level today.
For Atara Biotherapeutics stocks, the 200-day moving average is the resistance level today.
Are you interested in Atara Biotherapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Atara Biotherapeutics stock price in 2022, 2023, 2024, 2025, 2026. How much will one Atara Biotherapeutics share be worth in 2022 - 2026?
When should I take profit in Atara Biotherapeutics stock? When should I record a loss on Atara Biotherapeutics stock? What are analysts' forecasts for Atara Biotherapeutics stock? What is the future of Atara Biotherapeutics stock?
We forecast Atara Biotherapeutics stock performance using neural networks based on historical data on Atara Biotherapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Atara Biotherapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026)
The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Atara Biotherapeutics shares. This happens once a day.
Historical and forecast chart of Atara Biotherapeutics stock
The chart below shows the historical price of Atara Biotherapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Atara Biotherapeutics stock price can be found in the table below.
Long-term forecasts by years.
Atara Biotherapeutics daily forecast for a month
Atara Biotherapeutics Daily Price Targets
Atara Biotherapeutics Stock Forecast 05-22-2022.
Pessimistic target level: 5.25
Optimistic target level: 5.43
Atara Biotherapeutics Stock Forecast 05-23-2022.
Pessimistic target level: 5.33
Optimistic target level: 5.48
Atara Biotherapeutics Stock Forecast 05-24-2022.
Pessimistic target level: 5.25
Optimistic target level: 5.49
Atara Biotherapeutics Stock Forecast 05-25-2022.
Pessimistic target level: 5.09
Optimistic target level: 5.27
Atara Biotherapeutics Stock Forecast 05-26-2022.
Pessimistic target level: 5.14
Optimistic target level: 5.29
Atara Biotherapeutics Stock Forecast 05-27-2022.
Pessimistic target level: 5.26
Optimistic target level: 5.40
ATRA (ATRA) Monthly Stock Prediction for 2022
Atara Biotherapeutics forecast for this year
Atara Biotherapeutics Stock Prediction for Jun 2022
An uptrend is forecast for this month with an optimal target price of $5.76277. Pessimistic: $5.41. Optimistic: $6.10
Atara Biotherapeutics Stock Prediction for Jul 2022
An uptrend is forecast for this month with an optimal target price of $5.97714. Pessimistic: $5.48. Optimistic: $6.21
Atara Biotherapeutics Stock Prediction for Aug 2022
An uptrend is forecast for this month with an optimal target price of $6.32143. Pessimistic: $5.81. Optimistic: $6.75
Atara Biotherapeutics Stock Prediction for Sep 2022
An downtrend is forecast for this month with an optimal target price of $6.2304. Pessimistic: $5.75. Optimistic: $6.78
Atara Biotherapeutics Stock Prediction for Oct 2022
An downtrend is forecast for this month with an optimal target price of $6.08834. Pessimistic: $5.72. Optimistic: $6.38
Atara Biotherapeutics Stock Prediction for Nov 2022
An downtrend is forecast for this month with an optimal target price of $6.07373. Pessimistic: $5.81. Optimistic: $6.48
Atara Biotherapeutics Stock Prediction for Dec 2022
An downtrend is forecast for this month with an optimal target price of $5.86966. Pessimistic: $5.59. Optimistic: $6.28
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2023
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2024
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2025
Atara Biotherapeutics (ATRA) Monthly Stock Prediction for 2026
Atara Biotherapeutics information and performance
Atara Biotherapeutic, Inc., a turnkey T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. He is developing tabelecleucel, a T-cell immunotherapy phase III clinical trial for the treatment of rituximab-refractory Epstein-Barr virus (EBV) associated with post-transplant lymphoproliferative disorder, as well as other EBV-related hematological and solid tumors, including carcinoma of the nasopharynx. The company is also developing next-generation CAR T immunotherapy for patients with hematologic malignancies and solid tumors, as well as viral diseases, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 For B-cell lymphomas, and ATA188, which are in phase I clinical trials for the treatment of multiple sclerosis. He also develops ATA2321 for acute myeloid leukemia; ATA230 for cytomegalovirus; ATA368 for HPV; ATA520 for Wilms tumor 1; and ATA621 for BK and JCV. The company has a licensing agreement with the Sloan Kettering Memorial Cancer Center; a license agreement for cooperation in research and development with the Kimr Berghofer Medical Research Institute; and strategic cooperation with the H. Lee Moffitt Cancer Center. Atara Biotherapeutic, Inc. The company was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics Address
611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA, US
Market Capitalization: 511 863 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: -279 340 992 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: None
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: N/A
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: -
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: -
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 8.43
Enterprise Value (EV) /Revenue
EV To EBITDA: -
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 93406000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.